Detalhe da pesquisa
1.
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status.
Blood
; 139(14): 2145-2155, 2022 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995344
2.
Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.
Haematologica
; 109(4): 1082-1094, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37941406
3.
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
Br J Haematol
; 201(6): 1129-1143, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990798
4.
Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse xenograft model.
Bioorg Med Chem Lett
; 26(3): 742-746, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26774655
5.
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Mol Cancer Ther
; 20(7): 1270-1282, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33879555
6.
A synthetic lethal screen reveals enhanced sensitivity to ATR inhibitor treatment in mantle cell lymphoma with ATM loss-of-function.
Mol Cancer Res
; 13(1): 120-9, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25232030
7.
The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo.
Mol Cancer Ther
; 11(3): 730-9, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22246440